Jefferies Financial Group Reiterates “Buy” Rating for BioNTech (NASDAQ:BNTX)

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reaffirmed by stock analysts at Jefferies Financial Group in a note issued to investors on Wednesday,MarketScreener Latest Ratings reports. They currently have a $151.00 price target on the stock. Jefferies Financial Group’s price objective points to a potential upside of 57.29% from the stock’s previous close.

A number of other research firms have also recently issued reports on BNTX. Bank of America decreased their price target on shares of BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a report on Wednesday, October 22nd. JPMorgan Chase & Co. reduced their target price on BioNTech from $121.00 to $120.00 and set a “neutral” rating for the company in a research note on Thursday, October 23rd. HC Wainwright boosted their price target on BioNTech from $136.00 to $140.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Cowen reissued a “hold” rating on shares of BioNTech in a report on Monday, November 3rd. Finally, Berenberg Bank reaffirmed a “buy” rating on shares of BioNTech in a report on Tuesday, November 25th. Ten investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and a consensus target price of $136.42.

BioNTech Trading Down 0.8%

Shares of NASDAQ:BNTX opened at $96.00 on Wednesday. The business’s 50-day moving average is $102.89 and its 200 day moving average is $105.13. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.12 and a quick ratio of 7.02. BioNTech has a 1 year low of $81.20 and a 1 year high of $129.27. The firm has a market capitalization of $21.62 billion, a P/E ratio of -36.50 and a beta of 1.30.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of $0.75 by ($0.89). BioNTech had a negative return on equity of 3.03% and a negative net margin of 17.91%.The business had revenue of $1.78 billion during the quarter, compared to analyst estimates of $1.21 billion. During the same period in the prior year, the business posted $0.81 EPS. BioNTech’s revenue was up 22.0% compared to the same quarter last year. On average, research analysts predict that BioNTech will post -3.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Hedge funds have recently bought and sold shares of the stock. Dodge & Cox increased its holdings in shares of BioNTech by 315.7% during the 3rd quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock valued at $359,676,000 after purchasing an additional 2,769,654 shares in the last quarter. BNP Paribas Financial Markets grew its position in BioNTech by 6.7% during the second quarter. BNP Paribas Financial Markets now owns 1,275,475 shares of the company’s stock valued at $135,800,000 after buying an additional 80,005 shares during the period. Bank of New York Mellon Corp increased its holdings in BioNTech by 58.8% in the second quarter. Bank of New York Mellon Corp now owns 1,108,719 shares of the company’s stock valued at $118,045,000 after buying an additional 410,351 shares in the last quarter. Franklin Resources Inc. raised its position in shares of BioNTech by 76.8% in the second quarter. Franklin Resources Inc. now owns 751,998 shares of the company’s stock worth $80,065,000 after acquiring an additional 326,556 shares during the period. Finally, Aberdeen Group plc boosted its stake in shares of BioNTech by 87.2% during the 2nd quarter. Aberdeen Group plc now owns 721,928 shares of the company’s stock worth $76,864,000 after acquiring an additional 336,260 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.